The anti-Ro/La autoantibodies profile did not significantly differ between the two groups (p = 0.262), though pSS-ILD patients with anti-Ro52+ autoantibodies (either isolated or combined with anti-Ro60 autoantibodies) were diagnosed with ILD after a significantly longer time since pSS diagnosis compared to seronegative pSS patients (p = 0.019) as shown in Figure 2. Here, TRIM21 is linked to interstitial lung disease.